secwatch.observer — SEC 8-K summary
======================================

Issuer:     Citius Pharmaceuticals, Inc. (CTXR)
CIK:        0001506251
Form:       8-K
Filed at:   2024-02-15T23:59:59+00:00
Accession:  0001213900-24-014332
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Citius Pharma Q1 net loss $9.2M; cash runway through Aug 2024
-------------------------------------------------------------

- Net loss of $9.2M ($0.06 per share) compared to loss of $3.6M ($0.02 per share) in prior year.
- Cash and equivalents $20.3M as of Dec 31, 2023; runway expected through August 2024.
- LYMPHIR BLA resubmitted to FDA; awaiting PDUFA date; merger of oncology subsidiary with TenX (TENK) expected H1 2024.
- Completed enrollment in Mino-Lok Phase 3 trial; topline results expected in Q2 2024.
- R&D expenses $2.6M (down from $3.4M); G&A expenses $3.7M (up from $2.6M).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024014332/0001213900-24-014332-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506251/000121390024014332/ea193774-8k_citius.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-014332

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer